263 related articles for article (PubMed ID: 34912334)
1. Double Strike Approach for Tumor Attack: Engineering T Cells Using a CD40L:CD28 Chimeric Co-Stimulatory Switch Protein for Enhanced Tumor Targeting in Adoptive Cell Therapy.
Olguín-Contreras LF; Mendler AN; Popowicz G; Hu B; Noessner E
Front Immunol; 2021; 12():750478. PubMed ID: 34912334
[TBL] [Abstract][Full Text] [Related]
2. Regulation of CD40 ligand expression on naive CD4 T cells: a role for TCR but not co-stimulatory signals.
Jaiswal AI; Dubey C; Swain SL; Croft M
Int Immunol; 1996 Feb; 8(2):275-85. PubMed ID: 8671613
[TBL] [Abstract][Full Text] [Related]
3. Synthetic dual co-stimulation increases the potency of HIT and TCR-targeted cell therapies.
Dobrin A; Lindenbergh PL; Shi Y; Perica K; Xie H; Jain N; Chow A; Wolchok JD; Merghoub T; Sadelain M; Hamieh M
Nat Cancer; 2024 May; 5(5):760-773. PubMed ID: 38503896
[TBL] [Abstract][Full Text] [Related]
4. Mechanistic basis of co-stimulatory CD40-CD40L ligation mediated regulation of immune responses in cancer and autoimmune disorders.
Chand Dakal T; Dhabhai B; Agarwal D; Gupta R; Nagda G; Meena AR; Dhakar R; Menon A; Mathur R; Mona ; Yadav V; Sharma A
Immunobiology; 2020 Mar; 225(2):151899. PubMed ID: 31899051
[TBL] [Abstract][Full Text] [Related]
5. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
[TBL] [Abstract][Full Text] [Related]
6. Anti-CD40 Antibody Fused to CD40 Ligand Is a Superagonist Platform for Adjuvant Intrinsic DC-Targeting Vaccines.
Ceglia V; Zurawski S; Montes M; Kroll M; Bouteau A; Wang Z; Ellis J; Igyártó BZ; Lévy Y; Zurawski G
Front Immunol; 2021; 12():786144. PubMed ID: 35095862
[TBL] [Abstract][Full Text] [Related]
7. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
[TBL] [Abstract][Full Text] [Related]
8. Programmed cell death protein 1 activation preferentially inhibits CD28.CAR-T cells.
Zolov SN; Rietberg SP; Bonifant CL
Cytotherapy; 2018 Oct; 20(10):1259-1266. PubMed ID: 30309710
[TBL] [Abstract][Full Text] [Related]
9. Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
Blood; 2002 Nov; 100(9):3155-63. PubMed ID: 12384413
[TBL] [Abstract][Full Text] [Related]
10. Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Haynes NM; Trapani JA; Teng MW; Jackson JT; Cerruti L; Jane SM; Kershaw MH; Smyth MJ; Darcy PK
J Immunol; 2002 Nov; 169(10):5780-6. PubMed ID: 12421958
[TBL] [Abstract][Full Text] [Related]
11. Priming of a novel subset of CD28+ rapidly expanding high-avidity effector memory CTL by post maturation electroporation-CD40L dendritic cells is IL-12 dependent.
DeBenedette MA; Calderhead DM; Ketteringham H; Gamble AH; Horvatinovich JM; Tcherepanova IY; Nicolette CA; Healey DG
J Immunol; 2008 Oct; 181(8):5296-305. PubMed ID: 18832685
[TBL] [Abstract][Full Text] [Related]
12. A novel chimeric antigen receptor containing a JAK-STAT signaling domain mediates superior antitumor effects.
Kagoya Y; Tanaka S; Guo T; Anczurowski M; Wang CH; Saso K; Butler MO; Minden MD; Hirano N
Nat Med; 2018 Mar; 24(3):352-359. PubMed ID: 29400710
[TBL] [Abstract][Full Text] [Related]
13. A TIGIT-based chimeric co-stimulatory switch receptor improves T-cell anti-tumor function.
Hoogi S; Eisenberg V; Mayer S; Shamul A; Barliya T; Cohen CJ
J Immunother Cancer; 2019 Sep; 7(1):243. PubMed ID: 31500665
[TBL] [Abstract][Full Text] [Related]
14. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
[TBL] [Abstract][Full Text] [Related]
15. Avoidance of On-Target Off-Tumor Activation Using a Co-stimulation-Only Chimeric Antigen Receptor.
Fisher J; Abramowski P; Wisidagamage Don ND; Flutter B; Capsomidis A; Cheung GW; Gustafsson K; Anderson J
Mol Ther; 2017 May; 25(5):1234-1247. PubMed ID: 28341563
[TBL] [Abstract][Full Text] [Related]
16. CD28 co-stimulation stabilizes the expression of the CD40 ligand on T cells.
Johnson-Léger C; Christensen J; Klaus GG
Int Immunol; 1998 Aug; 10(8):1083-91. PubMed ID: 9723694
[TBL] [Abstract][Full Text] [Related]
17. The role of CD40 ligand in costimulation and T-cell activation.
Grewal IS; Flavell RA
Immunol Rev; 1996 Oct; 153():85-106. PubMed ID: 9010720
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB and optimized CD28 co-stimulation enhances function of human mono-specific and bi-specific third-generation CAR T cells.
Roselli E; Boucher JC; Li G; Kotani H; Spitler K; Reid K; Cervantes EV; Bulliard Y; Tu N; Lee SB; Yu B; Locke FL; Davila ML
J Immunother Cancer; 2021 Oct; 9(10):. PubMed ID: 34706886
[TBL] [Abstract][Full Text] [Related]
19. Co-stimulatory molecules in islet xenotransplantation: CTLA4Ig treatment in CD40 ligand-deficient mice.
Benda B; Ljunggren HG; Peach R; Sandberg JO; Korsgren O
Cell Transplant; 2002; 11(7):715-20. PubMed ID: 12518898
[TBL] [Abstract][Full Text] [Related]
20. Adoptive transfer of murine T cells expressing a chimeric-PD1-Dap10 receptor as an immunotherapy for lymphoma.
Lynch A; Hawk W; Nylen E; Ober S; Autin P; Barber A
Immunology; 2017 Nov; 152(3):472-483. PubMed ID: 28670716
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
